Alprazolam

Jump to: navigation, search

Synonyms / Brand Names: Aloram, Alprax, Alplax, Alpronax, Alprox, Alzam, Anxirid, Apo-Alpraz, Azor, Calmax, Frontal, Frontin, Gerax, Helex, Kalma, Kinax, Neurol, Novo-Alprazol, Nu-Alpraz, Restyl, Trankimazin, Xanax, Xanor, Zopax, Trika, Bestrol, Cassadan, Constan, D 65MT, Esparon, Intensol, Niravam, Solanax, Tafil, Tranax, Tranquinal, Xanax XR. It is also commonly known as "Totem Poles" or "Ladders" or "Bars" or "Yellow Buses" or "French Fries" when laced, when sold or used illegally.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Dosing and Administration

Treatment for patients with anxiety should be initiated with a dose of 0.25 to 0.5 mg given three times daily.

In elderly patients, in patients with advanced liver disease or in patients with debilitating disease, the usual starting dose is 0.25 mg, given two or three times daily.

In controlled trials conducted to establish the efficacy of Alprazolam in panic disorder, doses in the range of 1 to 10 mg daily were used. The mean dosage employed was approximately 5 to 6 mg daily.

Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given above will meet the needs of most patients, there will be some who require doses greater than 4 mg/day. In such cases, dosage should be increased cautiously to avoid adverse effects.

In all patients, dosage should be reduced gradually when discontinuing therapy or when decreasing the daily dosage.



FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.

Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information

Trial Resources
Ongoing Trials, Trial Results

Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.

Media Resources
Slides, Video, Images, MP3, Podcasts, etc.

Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.

International Resources
en Español






FDA Package Insert Resources

Indications

Contraindications

Side Effects

Drug Interactions

Precautions

Overdose

Instructions for Administration

How Supplied

Pharmacokinetics and Molecular Data

FDA label

FDA on Alprazolam

Return to top

Publication Resources

Most Recent Articles on Alprazolam

Review Articles on Alprazolam

Articles on Alprazolam in N Eng J Med, Lancet, BMJ

Textbook Information on Alprazolam

Return to top

Trial Resources

Ongoing Trials with Alprazolam at Clinical Trials.gov

Trial Results with Alprazolam

Return to top

Guidelines & Evidence Based Medicine Resources

US National Guidelines Clearinghouse on Alprazolam

Cochrane Collaboration on Alprazolam

Cost Effectiveness of Alprazolam

Return to top

Media Resources

Powerpoint Slides on Alprazolam

Images of Alprazolam

Podcasts & MP3s on Alprazolam

Videos on Alprazolam

Return to top

Patient Resources

Patient Information from National Library of Medicine

Patient Resources on Alprazolam

Discussion Groups on Alprazolam

Patient Handouts on Alprazolam

Blogs on Alprazolam

Alprazolam in the News

Alprazolam in the Marketplace

Return to top

International Resources

Alprazolam en Español

Return to top


The content of this page is taken from the FDA package insert for this drug and should not be edited.


Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added Pictures

Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs

Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link Here
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Linked-in.jpg
Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox